Hjem › Myelodysplastiske syndromer › Ohio › Columbus
Kliniske studier for Myelodysplastiske syndromer i Columbus, OH
14 studier for Myelodysplastiske syndromer søker deltakere på steder i og rundt Columbus (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruttererFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RekruttererFase 1/2
- The Ohio State University, Columbus
Collection of Tissue Samples for Cancer Research
RekruttererObservasjonsstudie
- Ohio State University, Columbus
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
RekruttererFase 1
- Ohio State University, The James Comprehensive Cancer, Columbus
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RekruttererFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruttererFase 1/2
- Nationwide Children's Hospital, Columbus
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
RekruttererFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekruttererFase 2/3
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
RekruttererFase 1
- Ohio State University Medical Center, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruttererFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Columbus
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RekruttererFase 1
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
HPC Offered for PRESERVE Expansion
RekruttererObservasjonsstudie
- The Ohio State University Medical Center, Columbus
Myelodysplastiske syndromer-studier i andre byer
- Houston, TX43 studier
- Baldwin Park, CA26 studier
- New York City, NY21 studier
- Seattle, WA21 studier
- Washington, DC20 studier
- Tampa, FL19 studier
- Boston, MA19 studier
- Miami, FL17 studier
- Durham, NC14 studier
- St. Louis, MO13 studier
- Atlanta, GA13 studier
- Chicago, IL13 studier
Andre studier i Columbus
- Ikke-småcellet lungekreft57 studier
- Brystkreft40 studier
- Eggstokkreft39 studier
- Kreft (alle typer)38 studier
- Lungekreft37 studier
- Akut myelogen leukemi35 studier
- Kronisk lymfatisk leukemi28 studier
- Metastatisk kreft27 studier
- Endometriekreft25 studier
- Prostatakreft24 studier
- Multipelt myelom24 studier
- Kolorektal kreft24 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.